These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 31733426)

  • 1. Alemtuzumab treatment of multiple sclerosis in real-world clinical practice: A report from a single Italian center.
    di Ioia M; Di Stefano V; Farina D; Di Tommaso V; Travaglini D; Pietrolongo E; Sensi SL; Onofrj M; De Luca G
    Mult Scler Relat Disord; 2020 Feb; 38():101504. PubMed ID: 31733426
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Data of safety in a single-center alemtuzumab treated population.
    di Ioia M; Di Stefano V; Farina D; Di Tommaso V; Travaglini D; Pietrolongo E; Sensi SL; Onofrj M; De Luca G
    Data Brief; 2020 Apr; 29():105341. PubMed ID: 32181303
    [TBL] [Abstract][Full Text] [Related]  

  • 3. No evidence of disease activity (NEDA-3) and disability improvement after alemtuzumab treatment for multiple sclerosis: a 36-month real-world study.
    Prosperini L; Annovazzi P; Boffa L; Buscarinu MC; Gallo A; Matta M; Moiola L; Musu L; Perini P; Avolio C; Barcella V; Bianco A; Farina D; Ferraro E; Pontecorvo S; Granella F; Grimaldi LME; Laroni A; Lus G; Patti F; Pucci E; Pasca M; Sarchielli P;
    J Neurol; 2018 Dec; 265(12):2851-2860. PubMed ID: 30259178
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A real-world single-centre analysis of alemtuzumab and cladribine for multiple sclerosis.
    Bose G; Rush C; Atkins HL; Freedman MS
    Mult Scler Relat Disord; 2021 Jul; 52():102945. PubMed ID: 33901969
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alemtuzumab treatment in real clinical practice: Experience in a multicenter cohort.
    López-Real AM; Gonzalez I; Solar DM; Oterino A; Costa E; Pato A; Llaneza MA; García-Estévez DA; Rodriguez-Regal A; Rodriguez M; Peña J
    Mult Scler Relat Disord; 2023 Jul; 75():104762. PubMed ID: 37229800
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of alemtuzumab treatment in a real-world cohort of patients with multiple sclerosis.
    Zmira O; Halpern AI; Abraham L; Achiron A
    Acta Neurol Belg; 2021 Dec; 121(6):1513-1518. PubMed ID: 32447722
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mitigating alemtuzumab-associated autoimmunity in MS: A "whack-a-mole" B-cell depletion strategy.
    Meltzer E; Campbell S; Ehrenfeld B; Cruz RA; Steinman L; Parsons MS; Zamvil SS; Frohman EM; Frohman TC
    Neurol Neuroimmunol Neuroinflamm; 2020 Nov; 7(6):. PubMed ID: 32769201
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ocrelizumab in MS patients with persistence of disease activity after alemtuzumab: A multi-center Italian study.
    Lapucci C; Frau J; Cocco E; Coghe G; Petracca M; Lanzillo R; Brescia Morra V; Nicoletti CG; Landi D; Marfia G; Vercellino M; Cavalla P; Bianco A; Mirabella M; Torri Clerici V; Tomas E; Ferrò MT; Grossi P; Nozzolillo A; Moiola L; Zaffaroni M; Ronzoni M; Pinardi F; Novi G; Cellerino M; Uccelli A; Inglese M
    Mult Scler; 2024 Aug; 30(9):1151-1162. PubMed ID: 39143825
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A real-life study of alemtuzumab in persons with multiple sclerosis: Kuwait's experience.
    Alroughani R; AlMojel M; Al-Hashel J; Ahmed SF
    Mult Scler Relat Disord; 2023 Jun; 74():104712. PubMed ID: 37054581
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Simultaneous early-onset severe autoimmune hemolytic anemia and albuminuria during alemtuzumab treatment for multiple sclerosis.
    di Ioia M; Farina D; di Tommaso V; Travaglini D; Pietrolongo E; Onofrj M; de Luca G
    Mult Scler; 2018 May; 24(6):813-815. PubMed ID: 29359617
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A real-world cohort analysis of alemtuzumab outcomes in relapsing multiple sclerosis.
    Herman JA; Khalighinejad F; York K; Radu I; Berrios Morales I; Ionete C; Hemond CC
    Mult Scler Relat Disord; 2021 Jan; 47():102619. PubMed ID: 33189019
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alemtuzumab treatment for multiple sclerosis in Austria: An observational long-term outcome study.
    Moser T; Foettinger F; Hitzl W; Novotna B; Berger T; Bsteh G; Di Pauli F; Hegen H; Kornek B; Langenscheidt D; Sellner J
    Ann Clin Transl Neurol; 2024 Jun; 11(6):1442-1455. PubMed ID: 38715245
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Switching from fingolimod to alemtuzumab in patients with highly active relapsing-remitting multiple sclerosis: Α case series.
    Notas K; Papadaki E; Orologas A; Moschou M; Kimiskidis VK
    Mult Scler Relat Disord; 2020 Feb; 38():101517. PubMed ID: 31751858
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Outcomes after fingolimod to alemtuzumab treatment shift in relapsing-remitting MS patients: a multicentre cohort study.
    Frau J; Saccà F; Signori A; Baroncini D; Fenu G; Annovazzi P; Capobianco M; Signoriello E; Laroni A; La Gioia S; Sartori A; Maniscalco GT; Bonavita S; Clerico M; Russo CV; Gallo A; Lapucci C; Carotenuto A; Sormani MP; Cocco E;
    J Neurol; 2019 Oct; 266(10):2440-2446. PubMed ID: 31209573
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Siponimod following Alemtuzumab in secondary progressive MS: investigating sequential therapy-A case series.
    Zanghì A; Di Filippo PS; Avolio C; D'Amico E
    Mult Scler Relat Disord; 2024 Oct; 90():105795. PubMed ID: 39151236
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of alemtuzumab in a real-life cohort of patients with multiple sclerosis.
    Frau J; Coghe G; Lorefice L; Fenu G; Musu L; Cocco E
    J Neurol; 2019 Jun; 266(6):1405-1411. PubMed ID: 30863891
    [TBL] [Abstract][Full Text] [Related]  

  • 17. aHSCT is superior to alemtuzumab in maintaining NEDA and improving cognition in multiple sclerosis.
    Häußler V; Ufer F; Pöttgen J; Wolschke C; Friese MA; Kröger N; Heesen C; Stellmann JP
    Ann Clin Transl Neurol; 2021 Jun; 8(6):1269-1278. PubMed ID: 33949790
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lymphocyte pharmacodynamics are not associated with autoimmunity or efficacy after alemtuzumab.
    Wiendl H; Carraro M; Comi G; Izquierdo G; Kim HJ; Sharrack B; Tornatore C; Daizadeh N; Chung L; Jacobs AK; Hogan RJ; Wychowski LV; Van Wijmeersch B;
    Neurol Neuroimmunol Neuroinflamm; 2020 Jan; 7(1):. PubMed ID: 31662412
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety of alemtuzumab in a nationwide cohort of Finnish multiple sclerosis patients.
    Rauma I; Mustonen T; Seppä JM; Ukkonen M; Männikkö M; Verkkoniemi-Ahola A; Kartau M; Saarinen JT; Luostarinen L; Simula S; Ryytty M; Ahmasalo R; Sipilä JOT; Pieninkeroinen I; Tapiola T; Remes AM; Kuusisto H
    J Neurol; 2022 Feb; 269(2):824-835. PubMed ID: 34255182
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Life-threatening autoimmune warm hemolytic anemia following treatment for multiple sclerosis with alemtuzumab.
    Meunier B; Rico A; Seguier J; Boutiere C; Ebbo M; Harle JR; Schleinitz N; Pelletier J
    Mult Scler; 2018 May; 24(6):811-813. PubMed ID: 29359614
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.